BRYJA, Vítězslav, Pavel KREJČÍ, Markéta KAUCKÁ, Šárka POSPÍŠILOVÁ, Jiří MAYER, Alois KOZUBÍK, Jana KOTAŠKOVÁ and Karla PLEVOVÁ. Method of Determination of Diagnosis and Prognosis in Patients with B-cell Chronic Lymphocytic leukemia and oligonucleotides for use in this method. 2015.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Method of Determination of Diagnosis and Prognosis in Patients with B-cell Chronic Lymphocytic leukemia and oligonucleotides for use in this method
Authors BRYJA, Vítězslav (203 Czech Republic, guarantor, belonging to the institution), Pavel KREJČÍ (203 Czech Republic, belonging to the institution), Markéta KAUCKÁ (203 Czech Republic), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Alois KOZUBÍK (203 Czech Republic, belonging to the institution), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution) and Karla PLEVOVÁ (203 Czech Republic, belonging to the institution).
Edition Number: US 9,057,106, Publisher: United States Patents and Trademark, Place of publication: USA, Owner's name: Masarykova univerzita, 2015.
Other information
Original language English
Type of outcome Patent
Field of Study Genetics and molecular biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/15:00087216
Organization unit Faculty of Science
Keywords in English B Cell; Chronic Lymphotetic Leukemia; WNT/PCP Signaling Pathway
Tags AKR, rivok
Changed by Changed by: Ing. Andrea Mikešková, učo 137293. Changed: 8/4/2016 09:00.
Abstract
The invention provides a method of determination of diagnosis and prognosis of B-cell chronic lymphocytic leukemia from a biological sample collected from the body of a patient, wherein the status of Wnt/PCP signaling pathway is determined. Within the framework of the present invention the relation of CLL and molecular signaling pathway Wnt/PCP the components of which are markedly up-regulated in B-lymphocytes of the patients suffering from CLL was identified. The status of the Wnt/PCP signaling pathway can be determined, e.g., by the determination of the expression of components of said signaling pathway or by the determination of migration of CLL cells in the gradient of a chemokine in the presence of the ligand of said signaling pathway. The invention also relates to suitable oligonucleotides for use in the method of determination of expression of the signaling pathway components.
PrintDisplayed: 30/5/2024 08:49